A consortium of investors led a $25m Series B round in Codagenix, a biotechnology research company, with participation from Serum Institute of India, Euclidean Capital and Adjuvant Capital. “It is exciting to now have the Serum Institute of India as a direct investor, building upon our successful partnership in the development of CoviLiv and, of course, we thank Euclidean Capital and Adjuvant Capital for their continued support and belief in our differentiated platform. This financing positions us well to advance our deep clinical pipeline, including live-attenuated vaccine candidates in RSV, that has the potential to meet a critical unmet need as well as further demonstrate our platform’s ability to design custom virotherapeutics for solid-tumors,” J. Robert Coleman, Codagenix Co-Founder and CEO.